Leerink analyst Jonathan Chang downgraded Mersana Therapeutics (MRSN) to Market Perform from Outperform with a $29 price target after Day One Biopharmaceuticals (DAWN) agreed to buy the company for $25 per share in cash at closing plus one CVR worth up to an aggregate of $30.25 in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana Therapeutics downgraded to Hold from Buy at Truist
- Oppenheimer says Day One paying up to $285M for Mersana ‘is interesting’
- Mersana Therapeutics downgraded to Neutral from Buy at BTIG
- Mersana Therapeutics up 201% at $26.70 after being acquired by Day One Biopharma
- Mersana Therapeutics downgraded to Neutral from Outperform at Wedbush